When Conflict of Interest Shapes the Narrative ~ and the Person Pays the Price
People living with multiple sclerosis are routinely told that “there is no cure, but it can be treated” — and then presented with a tightly curated menu of options that overwhelmingly prioritise pharmaceutical disease-modifying therapies (DMTs). What is far less visible to the patient is how institutional conflict of interest quietly shapes what is promoted, tolerated, marginalised, or dismissed in official guidance.
The document Wellness practices and complementary therapies in multiple sclerosis, produced by the Multiple Sclerosis International Federation, makes this tension explicit in its own disclaimer. It states that the guide received financial support from Merck, Roche, and Novartis, three of the largest manufacturers of MS drugs, while asserting that editorial control was retained by the organisation. That disclosure matters. Not because it implies bad faith — but because funding structures influence framing, emphasis, and thresholds of “acceptable evidence”, whether consciously or not .
As a result, the guide systematically categorises non-drug approaches into narrow buckets:
- “wellness practices” (exercise, diet, stress reduction),
- “therapies that may have some benefit”, and
- long lists of approaches deemed unproven, unsafe, or unsupported.
What’s striking is not just what is included — yoga, meditation, massage, limited dietary patterns — but what is excluded or reduced to vague caution. Nutrients, phytochemicals, mitochondrial cofactors, redox modulators, and systems-level metabolic supports are largely absent as meaningful contributors, despite extensive literature on inflammation, oxidative stress, mitochondrial dysfunction, blood–brain barrier integrity, and neurodegeneration in MS. The patient is left with the impression that anything outside the drug pathway is, at best, marginal and, at worst, suspect.
This is where the conflict of interest lands squarely on the person with MS. The absence of certain ingredients or strategies from official lists is easily misread as evidence of ineffectiveness, when in reality it often reflects research funding priorities, trial economics, and regulatory convenience, not biological irrelevance. Non-patentable compounds rarely receive the scale of trials demanded for endorsement, even when their safety profiles are strong and their mechanisms align with known MS pathology.
Only at the end of this discussion does Marns Functional Smoothies (MFS) enter the picture — and deliberately so. MFS does not claim to cure MS, replace DMTs, or override medical care. Its framework targets supportive biology: reducing inflammatory burden, supporting mitochondrial energy production, buffering oxidative stress, stabilising neurochemistry, and preserving repair capacity over time. The fact that these ingredients do not appear on pharma-aligned MS “benefit” lists is not surprising. It is structural, not scientific.
In short, the problem is not that people with MS are being lied to outright. It’s that they are navigating a landscape where what is visible is heavily shaped by who pays for the map — and the cost of that distortion is borne by the individual trying to make informed decisions about their own body and future.
Leave a Reply